menu

FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin

    The FDA concluded that the type 2 diabetes medicine canagliflozin causes an increased risk of leg and foot amputations.
    • Overview

      Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, be added to the canagliflozin drug labels to describe this risk.

      Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs.

      Report side effects involving canagliflozin and other medicines to the FDA MedWatch program at fda.gov/medwatch.

      A link to the full communication detailing specific information for health care professionals and the complete Data Summary can be found at fda.gov/DrugSafetyCommunications. If you have drug questions, contact the FDA at druginfo@fda.hhs.gov.

      Released 5/16/2017

    Facebook Comments

    You must be in to display playlists.

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.